Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:36 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
NCT03281369 · Hoffmann-La Roche · PHASE1/PHASE2 · terminated · last registry update 2026-08-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was closed because the sponsor decided not to continue the development of certain treatment combinations.” | – | Registry record, Hoffmann-La Roche |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TYMS within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-10Also stopped (suspended): National Cancer Institute (NCI), azacytidine + carboplatin (NCT06694454)
- 2026-11-04Phase 3 first posted: Zhai Wenlong, Oxaliplatin + 5-Fluorouracil (NCT07916844)
- 2026-11-04Results posted on the registry: Cardiff Oncology, Onvansertib + Nanoliposomal irinotecan (NCT04752696)
- 2026-11-04Also stopped (terminated): Cardiff Oncology, Onvansertib + Nanoliposomal irinotecan (NCT04752696)
- 2026-11-04Results posted on the registry: University of Nebraska, Capecitabine + Fluorouracil (NCT03073785)
- 2026-11-04Phase 3 first posted: Innovent Biologics (Suzhou) Co. Ltd., Oxaliplatin + Placebo (NCT07917468)
- 2026-11-04Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Nab-paclitaxel + Gemcitabine (NCT04753879)
- 2026-11-04Also stopped (terminated): InnoPharmax Inc., D07001-softgel capsules + Xeloda (or TS-1) + mFOLFOX (NCT05065957)
- 2026-11-04Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, a drug against TYMS (NCT07915037)
- 2026-11-04Results posted on the registry: Jazz Pharmaceuticals, ZW25 (Zanidatamab) + Capecitabine (NCT03929666)
- 2026-11-03Also stopped (terminated): Peking University Cancer Hospital & Institute, KN046 + regorafenib (NCT05985109)
- 2026-11-02Phase 3 first posted: Tata Memorial Hospital, Capecitabine + Temozolomide (TMZ) (NCT07910760)
- 2026-10-30Results posted on the registry: Memorial Sloan Kettering Cancer Center, Bevacizumab HAI plus systemic chemotherapy + HAI plus systemic chemotherapy (NCT00200200)
- 2026-10-30Also stopped (terminated): Tufts Medical Center, Granulocyte-Macrophage Colony-Stimulating Factor + Pembrolizumab (NCT04856176)
- 2026-10-27Results posted on the registry: Georgetown University, Nanoliposomal Irinotecan + Leucovorin (NCT04005339)
- 2026-10-27Phase 3 first posted: Jiangsu Aosaikang Pharmaceutical Co., Ltd., ASKC202 + ASKC202 placebo (NCT07897188)
- 2026-10-26Phase 3 first posted: Suzhou Suncadia Biopharmaceuticals Co., Ltd., SHR-A1811 Injection + Adebrelimab Injection (NCT07896005)
- 2026-10-26Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., Investigator's Choice Chemotherapy (FOLFIRI or FOLFOX regimen) + QLC5508 (NCT07894211)
- 2026-10-22Also stopped (terminated): Oslo University Hospital, Floxuridine (NCT04898504)
- 2026-10-22Results posted on the registry: Takeda, Dazostinag + Pembrolizumab (NCT04420884)
- 2026-10-21Results posted on the registry: University of Nebraska, Digoxin + 5Fluorouracil (NCT04141995)
- 2026-10-21Also stopped (terminated): University of Nebraska, Digoxin + 5Fluorouracil (NCT04141995)
- 2026-10-21Phase 3 first posted: West China Hospital, Fruquintinib Combined With Capecitabine (NCT07885384)
- 2026-10-16Phase 3 first posted: German Cancer Research Center, Pembrolizumab + Carboplatin (AUC 5) (NCT07877584)
- 2026-10-15Also stopped (terminated): Spanish Breast Cancer Research Group, Trastuzumab + Alpelisib (NCT05063786)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision